XRad Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

XRad Therapeutics General Information

Description

Operator of a biotechnology company intended to develop dual kinase inhibitors for treating cancer. The company develops dual inhibitors of ataxia-telangiectasia mutated (ATM) and DNA-dependent protein kinase, evaluating the potential benefits of using them in combination with targeted radionuclides, checkpoint inhibitors, polyadenosine diphosphate-ribose polymerase (PARP) inhibitors, and antibody-drug conjugates (ADCs), providing healthcare professionals with therapeutics for the treatment of metastatic, locally-advanced, or recurrent solid tumors.

Contact Information

Website
www.xradtx.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 7 Essex Street
  • Suite 3B
  • New York, NY 10002
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 7 Essex Street
  • Suite 3B
  • New York, NY 10002
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

XRad Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 09-Oct-2024 Completed Out of Business
2. Later Stage VC (Series B) 24-Feb-2021 Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 19-Dec-2017 $499K $499K Completed Clinical Trials - Phase 1
To view XRad Therapeutics’s complete valuation and funding history, request access »

XRad Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view XRad Therapeutics’s complete cap table history, request access »

XRad Therapeutics Patents

XRad Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024186805-A1 Methods of treating cancer Inactive 06-Mar-2023
EP-4288423-A1 Combination of dual atm and dna-pk inhibitors and immunotherapeutic agents for use in cancer therapy Inactive 03-Feb-2021
EP-4288423-A4 Combination of dual atm and dna-pk inhibitors and immunotherapeutic agents for use in cancer therapy Inactive 03-Feb-2021
US-20250268873-A1 Combination of dual atm and dna-pk inhibitors and immunotherapeutic agents for use in cancer therapy Pending 03-Feb-2021
WO-2022169840-A1 Combination of dual atm and dna-pk inhibitors and immunotherapeutic agents for use in cancer therapy Inactive 03-Feb-2021 C07D471/04
To view XRad Therapeutics’s complete patent history, request access »

XRad Therapeutics FAQs

  • When was XRad Therapeutics founded?

    XRad Therapeutics was founded in 2016.

  • Where is XRad Therapeutics headquartered?

    XRad Therapeutics is headquartered in New York, NY.

  • What industry is XRad Therapeutics in?

    XRad Therapeutics’s primary industry is Biotechnology.

  • Is XRad Therapeutics a private or public company?

    XRad Therapeutics is a Private company.

  • What is XRad Therapeutics’s current revenue?

    The current revenue for XRad Therapeutics is .

  • How much funding has XRad Therapeutics raised over time?

    XRad Therapeutics has raised $2M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process